Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Lee

Clinical Cardiac Electrophysiology Lexington, KY Medical Doctor

NPI 1033521174 CMS profile 2884248

1720 Nicholasville Rd Ste 400, Lexington, KY 40503

Open in the dashboard

General payments

$139,244

826 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Lee of Lexington, KY is reported in the CMS Open Payments database as having received $139,244 across 826 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $36,404 150
2024 General $21,837 181
2023 General $27,120 188
2022 General $30,162 115
2021 General $15,129 69
2020 General $857 23
2019 General $7,734 100

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Lee
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to John Lee were reported at $36,404. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year John Lee Clinical Cardiac Electrophysiology median Middle half National median
2019 $7,734 $2,361 $585–$8,260 $163
2020 $857 $993 $247–$4,351 $114
2021 $15,129 $1,185 $326–$4,739 $132
2022 $30,162 $2,073 $554–$6,789 $149
2023 $27,120 $2,568 $759–$8,159 $160
2024 $21,837 $2,557 $703–$7,403 $164
2025 $36,404 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $46,089 179 payments
  2. Biotronik Inc. $31,090 185 payments
  3. Medtronic, Inc. $29,755 153 payments
  4. Boston Scientific Corporation $20,508 99 payments
  5. Philips Electronics North America Corporation $2,346 24 payments
  6. Medical Device Business Services, Inc. $1,705 5 payments
  7. Medtronic Vascular, Inc. $1,528 19 payments
  8. Stereotaxis Inc $862 6 payments
  9. Biosense Webster, Inc. $696 16 payments
  10. Amgen Inc. $633 16 payments
  11. Other $4,032 124 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $64,531 228 payments
  2. Food and Beverage $33,247 567 payments
  3. Grant $19,500 5 payments
  4. Consulting Fee $14,403 4 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $4,875 3 payments
  6. Education $2,101 14 payments
  7. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $500 1 payment
  8. Entertainment $87 4 payments
Products named General payments · program years 2019–2025
  1. AMPLATZER AMULET $26,547 58 payments
  2. BioMonitor $6,792 34 payments
  3. Solia $6,528 32 payments
  4. Acticor 7 VR-T DX $4,816 19 payments
  5. Rivacor $4,602 28 payments
  6. Edora $4,602 28 payments
  7. Acticor $4,602 28 payments
  8. Rivacor 7 DR-T $4,092 11 payments
  9. Edora 8 DR-T $3,929 10 payments
  10. EMBLEM S ICD ELECTRODE DELIVERY SYSTEM $3,750 1 payment
  11. Other $46,174 470 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

397

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$96,351

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

40.1%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 91 $75,863
Xarelto Rivaroxaban Brand 18 $15,866
Flecainide Acetate Generic 49 $2,342
Amiodarone Hcl Generic 58 $706
Metoprolol Succinate Generic 61 $703
Clopidogrel Clopidogrel Bisulfate Brand 50 $496
Metoprolol Tartrate Generic 38 $280
Carvedilol Generic 20 $80
Prednisone Generic 12 $14

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 77 billing codes

Paid by Medicare

$202,602

Medicare's payments for the services billed

Medicare patients

822

Average age 76

Services billed

2,679

427 women, 395 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 62%
Ischemic heart disease 58%
Arthritis 56%
Heart failure 46%
Diabetes 42%
Chronic kidney disease 39%
Depression 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYNDAQEL
  • PFIZER INC. $85
$85 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $38
  • PFIZER INC. $26
$64 91 —
BRILINTA
  • AstraZeneca Pharmaceuticals LP $37
$37 — —
NURTEC ODT
  • PFIZER INC. $20
$20 — —
PAXLOVID
  • PFIZER INC. $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

826 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record